Lantern Pharma to Present AI-Driven Oncology Platform at ThinkEquity Conference

Lantern Pharma (NASDAQ: LTRN), an artificial intelligence company specializing in oncology drug discovery, announced its management team will present at the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental in New York. The presentation scheduled for 11:30 a.m. ET will showcase the company's AI-driven approach to transforming cancer therapy development.

The company's proprietary RADR platform represents a significant advancement in pharmaceutical research, leveraging over 200 billion oncology-focused data points and more than 200 machine learning algorithms. This technology addresses critical challenges in drug development by potentially reducing costs and accelerating timelines for bringing new cancer treatments to market. The platform's ability to process massive datasets could fundamentally change how pharmaceutical companies approach oncology research.

Lantern Pharma's current pipeline includes multiple clinical-stage programs, featuring a Phase 2 clinical program and several Phase 1 trials spanning both solid tumors and blood cancers. The company has also developed an antibody-drug conjugate program, demonstrating the breadth of its AI-driven discovery capabilities. These developments are particularly significant given the company's estimate that its pipeline represents a combined annual market potential exceeding $15 billion.

The implications of Lantern Pharma's technology extend beyond financial metrics to potential patient impact. The company's approach could lead to life-changing therapies for hundreds of thousands of cancer patients worldwide by identifying promising drug candidates more efficiently than traditional methods. This efficiency gain comes at a crucial time when cancer rates continue to rise globally, creating urgent need for more effective and accessible treatments.

For investors and the pharmaceutical industry, Lantern Pharma's presentation at the ThinkEquity Conference offers insight into how AI is reshaping drug discovery. The company's progress demonstrates the growing role of technology in addressing some of healthcare's most challenging problems. Additional information about Lantern Pharma's developments is available in the company's newsroom at https://ibn.fm/LTRN.

The broader investment community can access comprehensive financial communications through platforms like InvestorWire, which provides specialized wire-grade press release syndication and corporate communications solutions. More details about these services are available at https://www.InvestorWire.com.